Held, never flipped
Privately held through the entire genomics build-out. One open listing, through one broker.
Privately held through the entire genomics build-out. One open listing, through one broker.
Disclosed category-name sales cluster between $4.8M and $35.6M. Do the multiple yourself.
Epi — “above.” Genome — the code. The science is converging on one word, and this is its .com.
Funds held by a licensed third party, released only after the name is in your account.
I don't write a page for every domain that crosses my desk. Most don't earn one. EPIGENOME.COM does, and the reason is simple: it is the one-word name of an entire scientific category, and names like that change hands once.
This name has been held privately through the entire genomics build-out — through the sequencing boom, through the first epigenetic therapies reaching patients, through every cycle in which a buyer might have pried it loose. It was never developed, never flipped, never listed. The reason it is on the market now is not timing or trend. It is a specific change in the holder's situation, and I would rather walk you through it on a call than flatten it into a paragraph.
What I can put in writing: the seller has authorized one open listing, through me, at a number I considered defensible before I agreed to represent it.
The genome was the last century's map. The epigenome is this century's control panel — the chemical layer that decides which genes are expressed, silenced or amplified. Drug programs, diagnostics, sequencing platforms and longevity clinics are converging on the same vocabulary, and the vocabulary converges on one word.
Type the science into any search engine, any grant database, any regulatory filing. The word is epigenome. There is exactly one .com that is the word itself, with nothing added and nothing to explain.
Brokers say “category-defining” the way realtors say “charming.” I'll use the phrase once, and then show you the math instead. Below are disclosed, lump-sum sales of names that are — or contain — the exact word for their category.
EPIGENOME.COM is not nine letters and an extension. It is what owning the category's name makes possible — and what not owning it costs, quietly, every year a competitor holds it instead.
The partners open your deck. The name is the category, so the first thirty seconds of credibility work are already done before anyone speaks. The meeting starts ahead of where it would have — every meeting does, for the next twenty years.
The headline writes itself, because the name is the noun the journalist was going to use anyway. Your competitor's announcement needs a second line to explain what they do. Yours doesn't.
Five years from now, the category leader's counsel asks what it would take to get the name from you. The answer is a number with more zeros than this page — and the leverage runs in your direction, permanently.
USD · lump sum · full ownership
One number, no auction theater. The transfer runs through Escrow.com: funds are held by a licensed third party and release only after the name is in your account — typically within days. No recurring fees, no renewal traps, nothing left to negotiate except whether you want it.
I broker ultra-premium names at GoDaddy. A handful cross that desk in a given year; fewer earn a page like this one. I have been wrong about a name before — it has been a while.
If you operate in genomics, diagnostics, therapeutics or longevity, you already know why the word matters. My job is simpler: tell you it is available, show you the math, and get out of the way of your decision.
Tom McCarthyGoDaddy
If the name is on your radar, the most efficient next step is a fifteen-minute call. I'll walk you through the full comp set, the seller's position, and where I think this lands in the next ninety days. You decide from there.
Written offers work too — the form routes directly to me, and I answer the serious ones the same day.
— Tom McCarthy · GoDaddy